Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

DISEASE CHARACTERISTICS: * Histologically confirmed ocular melanoma * Stage IV disease * Measurable disease * No active brain metastases * Patients with brain metastases must have had a complete excision or radiotherapy and remain asymptomatic with stable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan for ≥ 6 months PATIENT CHARACTERISTICS: * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Life expectancy \> 3 months * Granulocyte count \> 1,500/mm\^3 * Platelet count \> 100,000/mm\^3 * Creatinine ≤ 1.5 mg/dL OR creatinine clearance \> 60 mL/min * Bilirubin ≤ 2.0 mg/dL * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 10 times upper limit of normal (ULN) * Prothrombin time (PT)/partial thromboplastin time (PTT)/International Normalized Ratio (INR) normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use one highly effective method of contraception (with an additional method) or barrier methods of contraception for ≥ 4 weeks before, during, and for ≥ 4 weeks after completion of study therapy * Ejection fraction normal by echocardiogram * No acute, critical illness, including serious untreated infection * No history of any of the following: * Unstable or newly diagnosed angina pectoris * Myocardial infarction within the past 6 months * New York Heart Association class II-IV heart disease * Congestive heart failure * Chronic obstructive lung disease requiring…